Literature DB >> 20541673

Pheochromocytoma and paraganglioma.

Vitaly Kantorovich1, Karel Pacak.   

Abstract

Pheochromocytoma is a very special kind of tumor full of duplicity. On the one hand it represents its own microworld with unique clinical, biochemical and pathological features, while on the other it constitutes a tremendously significant part of whole body system, playing a vital role for practically every organ system. It has a very special character - sometimes like a child it can be sweet and predictable, while at times it can behave like a deadly wild beast, crashing and tearing everything on its path in a fierce rage. It also consists of the amazingly intelligent neuroendocrine cells that possess a magical ability to make miraculous substances of many kinds. But most of all, it is a system that is able to drive our curiosity and the itch of "Cogito, ergo sum" to limitless depths and year by year it still amazes us with new and unexpected discoveries that move our understanding of multiple pathways and metabolic events closer to the ultimate truth. Recent discoveries of succinate dehydrogenase (SHD) and prolyl hydroxylase (PHD) mutations, for example, propelled our understanding of neuroendocrine tumorigenesis as a whole, as well as physiology of mitochondrial respiratory chain and phenomenon of pseudohypoxia in particular. Good old discoveries make their way from dusty repositories to shine with new meaning, appropriate for the current level of knowledge. This acquired wisdom makes us better physicians - knowing the specific expression makeup of catecholamine transporters, GLUTs and SRIFs allows for better tailored imaging and therapeutic manipulations. There are still long ways to go, keeping in mind that pheochromocytoma is but so very special, and we are optimistic and expect many great things to come. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541673      PMCID: PMC4714594          DOI: 10.1016/S0079-6123(10)82015-1

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  212 in total

1.  [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.

Authors:  E van der Harst; W W de Herder ; H A Bruining; H J Bonjer; R R de Krijger ; S W Lamberts; A H van de Meiracker ; F Boomsma; T Stijnen; E P Krenning; F T Bosman; D J Kwekkeboom
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  Innovar-induced hypertensive crises in patients with pheochromocytoma.

Authors:  D A Bittar
Journal:  Anesthesiology       Date:  1979-04       Impact factor: 7.892

3.  Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2.

Authors:  A L Steiner; A D Goodman; S R Powers
Journal:  Medicine (Baltimore)       Date:  1968-09       Impact factor: 1.889

4.  SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling.

Authors:  William G Kaelin
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

5.  Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes.

Authors:  G Eisenhofer; M M Walther; T T Huynh; S T Li; S R Bornstein; A Vortmeyer; M Mannelli; D S Goldstein; W M Linehan; J W Lenders; K Pacak
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

6.  Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases.

Authors:  S Casanova; M Rosenberg-Bourgin; D Farkas; C Calmettes; N Feingold; H M Heshmati; R Cohen; B Conte-Devolx; P J Guillausseau; C Houdent
Journal:  Clin Endocrinol (Oxf)       Date:  1993-05       Impact factor: 3.478

7.  Pheochromocytoma and prazosin.

Authors:  J P Nicholson; E D Vaughn; T G Pickering; L M Resnick; J Artusio; H D Kleinert; J A Lopez-Overjero; J H Laragh
Journal:  Ann Intern Med       Date:  1983-10       Impact factor: 25.391

Review 8.  New imaging approaches to phaeochromocytomas and paragangliomas.

Authors:  Bas Havekes; Kathryn King; Edwin W Lai; Johannes A Romijn; Eleonora P M Corssmit; Karel Pacak
Journal:  Clin Endocrinol (Oxf)       Date:  2009-06-08       Impact factor: 3.478

9.  The origin of gut and pancreatic neuroendocrine (APUD) cells--the last word?

Authors:  A Andrew; B Kramer; B B Rawdon
Journal:  J Pathol       Date:  1998-10       Impact factor: 7.996

10.  The value of plasma markers for the clinical behaviour of phaeochromocytomas.

Authors:  E van der Harst; W W de Herder; R R de Krijger; H A Bruining; H J Bonjer; S W J Lamberts; A H van den Meiracker; T H Stijnen; F Boomsma
Journal:  Eur J Endocrinol       Date:  2002-07       Impact factor: 6.664

View more
  21 in total

Review 1.  Pheochromocytoma: The First Metabolic Endocrine Cancer.

Authors:  Ivana Jochmanova; Karel Pacak
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

2.  Phaeochromocytoma: a catecholamine and oxidative stress disorder.

Authors:  K Pacak
Journal:  Endocr Regul       Date:  2011-04

3.  Attention Deficit Hyperactivity Disorder in Pediatric Patients with Pheochromocytoma and Paraganglioma.

Authors:  M Batsis; U Dagalakis; C A Stratakis; T Prodanov; G Z Papadakis; K Adams; M Lodish; K Pacak
Journal:  Horm Metab Res       Date:  2016-05-12       Impact factor: 2.936

4.  Sodium butyrate reverses the inhibition of Krebs cycle enzymes induced by amphetamine in the rat brain.

Authors:  Samira S Valvassori; Karen V Calixto; Josiane Budni; Wilson R Resende; Roger B Varela; Karolina V de Freitas; Cinara L Gonçalves; Emilio L Streck; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2013-07-14       Impact factor: 3.575

5.  Development of pheochromocytoma in ceramide synthase 2 null mice.

Authors:  Woo-Jae Park; Ori Brenner; Aviram Kogot-Levin; Ann Saada; Alfred H Merrill; Yael Pewzner-Jung; Anthony H Futerman
Journal:  Endocr Relat Cancer       Date:  2015-06-25       Impact factor: 5.678

Review 6.  Pheochromocytoma: implications in tumorigenesis and the actual management.

Authors:  U Shah; A Giubellino; K Pacak
Journal:  Minerva Endocrinol       Date:  2012-06       Impact factor: 2.184

7.  Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma.

Authors:  Katerina Hadrava Vanova; Ying Pang; Linda Krobova; Michal Kraus; Zuzana Nahacka; Stepana Boukalova; Svetlana D Pack; Renata Zobalova; Jun Zhu; Thanh-Truc Huynh; Ivana Jochmanova; Ondrej Uher; Sona Hubackova; Sarka Dvorakova; Timothy J Garrett; Hans K Ghayee; Xiaolin Wu; Bjoern Schuster; Philip E Knapp; Zdenek Frysak; Igor Hartmann; Naris Nilubol; Jiri Cerny; David Taieb; Jakub Rohlena; Jiri Neuzil; Chunzhang Yang; Karel Pacak
Journal:  J Natl Cancer Inst       Date:  2022-01-11       Impact factor: 13.506

8.  Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects?

Authors:  Paraskevi Xekouki; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2012-10-30       Impact factor: 5.678

9.  Retroperitoneal paraganglioma: a chameleon masquerading as an adrenal pheochromocytoma.

Authors:  K Parmar; A Chandna; S Kumar
Journal:  Ann R Coll Surg Engl       Date:  2018-10-29       Impact factor: 1.891

Review 10.  Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease?

Authors:  Jenn Rachelle U Santos; Alessandra Brofferio; Bruna Viana; Karel Pacak
Journal:  Horm Metab Res       Date:  2018-09-18       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.